Naiyer A. Rizvi

64.8k total citations · 10 hit papers
275 papers, 15.0k citations indexed

About

Naiyer A. Rizvi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Naiyer A. Rizvi has authored 275 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 223 papers in Oncology, 153 papers in Pulmonary and Respiratory Medicine and 58 papers in Molecular Biology. Recurrent topics in Naiyer A. Rizvi's work include Lung Cancer Treatments and Mutations (140 papers), Cancer Immunotherapy and Biomarkers (134 papers) and Lung Cancer Research Studies (59 papers). Naiyer A. Rizvi is often cited by papers focused on Lung Cancer Treatments and Mutations (140 papers), Cancer Immunotherapy and Biomarkers (134 papers) and Lung Cancer Research Studies (59 papers). Naiyer A. Rizvi collaborates with scholars based in United States, Canada and France. Naiyer A. Rizvi's co-authors include Mark G. Kris, Vincent A. Miller, Scott Antonia, Matthew D. Hellmann, William Pao, Gregory J. Riely, Scott Gettinger, Laura Q.M. Chow, Christopher G. Azzoli and Lee M. Krug and has published in prestigious journals such as Nature, Science and Nature Medicine.

In The Last Decade

Naiyer A. Rizvi

267 papers receiving 14.7k citations

Hit Papers

Patient HLA class I genot... 2004 2026 2011 2018 2017 2016 2018 2004 2006 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
    2017 738 citations Diego Chowell, Luc G.T. Morris et al. Science profile →
  2. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
    2016 700 citations Matthew D. Hellmann, Naiyer A. Rizvi et al. profile →
  3. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
    2018 670 citations Matthew D. Hellmann, Naiyer A. Rizvi et al. profile →
  4. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
    2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
  5. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    2006 623 citations Gregory J. Riely, William Pao et al. Clinical Cancer Research profile →
  6. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
    2016 481 citations Sarah B. Goldberg, Ani Sarkis Balmanoukian et al. profile →
  7. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
    2017 445 citations Nadeem Riaz, Vladimir Makarov et al. profile →
  8. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
    2020 425 citations Catherine A. Shu, Claud Grigg et al. profile →
  9. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 394 citations Naiyer A. Rizvi, Rosalyn A. Juergens et al. Journal of Clinical Oncology profile →
  10. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 350 citations Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naiyer A. Rizvi United States 61 11.0k 7.7k 3.5k 3.0k 2.2k 275 15.0k
Scott Gettinger United States 58 10.3k 0.9× 6.8k 0.9× 2.8k 0.8× 2.8k 0.9× 1.7k 0.8× 258 13.2k
José Luis Perez‐Gracia Spain 51 10.4k 0.9× 5.0k 0.6× 2.8k 0.8× 5.7k 1.9× 1.9k 0.9× 191 15.2k
Amita Patnaik United States 62 8.4k 0.8× 4.5k 0.6× 6.2k 1.8× 2.7k 0.9× 2.1k 0.9× 365 14.4k
Frank G. Haluska United States 51 10.9k 1.0× 8.0k 1.0× 7.9k 2.2× 2.8k 0.9× 3.0k 1.4× 138 18.7k
Benjamin Besse France 64 12.2k 1.1× 10.4k 1.3× 5.6k 1.6× 2.2k 0.7× 3.8k 1.7× 708 18.8k
Kim Margolin United States 63 11.0k 1.0× 5.6k 0.7× 6.5k 1.8× 5.5k 1.8× 2.5k 1.1× 312 17.9k
Matthew D. Hellmann United States 61 16.4k 1.5× 9.0k 1.2× 4.1k 1.2× 4.9k 1.6× 2.7k 1.2× 231 21.4k
Craig Devoe United States 17 10.3k 0.9× 3.9k 0.5× 2.3k 0.6× 4.5k 1.5× 1.3k 0.6× 47 12.7k
Rolf A. Stahel Switzerland 64 5.8k 0.5× 6.9k 0.9× 4.4k 1.3× 1.5k 0.5× 1.9k 0.9× 326 14.1k
Laura Q.M. Chow United States 44 9.1k 0.8× 4.6k 0.6× 2.9k 0.8× 3.0k 1.0× 1.6k 0.7× 159 12.4k

Countries citing papers authored by Naiyer A. Rizvi

Since Specialization
Citations

This map shows the geographic impact of Naiyer A. Rizvi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naiyer A. Rizvi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naiyer A. Rizvi more than expected).

Fields of papers citing papers by Naiyer A. Rizvi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naiyer A. Rizvi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naiyer A. Rizvi. The network helps show where Naiyer A. Rizvi may publish in the future.

Co-authorship network of co-authors of Naiyer A. Rizvi

This figure shows the co-authorship network connecting the top 25 collaborators of Naiyer A. Rizvi. A scholar is included among the top collaborators of Naiyer A. Rizvi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naiyer A. Rizvi. Naiyer A. Rizvi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rizvi, Naiyer A., Eliseos J. Mucaki, Monica Zhang, et al.. (2025). Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy. Breast Cancer Research. 27(1). 127–127.
2.
Tawbi, Hussein A., Ryan J. Sullivan, David Feltquate, et al.. (2023). Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. Journal for ImmunoTherapy of Cancer. 11(7). e007309–e007309. 7 indexed citations
3.
4.
Rizvi, Naiyer A., Foluso O. Ademuyiwa, Z. Alexander Cao, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Journal for ImmunoTherapy of Cancer. 11(3). e005920–e005920. 24 indexed citations
5.
Washburn, Robert S., Radomir Kratchmarov, Shana M. Coley, et al.. (2022). Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy. Cancer Immunology Research. 11(2). 164–170. 13 indexed citations
6.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations
7.
Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations
8.
Balmanoukian, Ani Sarkis, Jeffrey R. Infante, Raid Aljumaily, et al.. (2020). Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clinical Cancer Research. 26(23). 6196–6203. 40 indexed citations
9.
Glisson, Bonnie S., Rom S. Leidner, Robert L. Ferris, et al.. (2020). Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(20). 5358–5367. 63 indexed citations
10.
Si, Han, Michael Kuziora, Katie Quinn, et al.. (2020). A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research. 27(6). 1631–1640. 86 indexed citations
11.
Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757. 38 indexed citations
12.
Chowell, Diego, Luc G.T. Morris, Claud Grigg, et al.. (2017). Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 359(6375). 582–587. 738 indexed citations breakdown →
13.
Drilon, Alexander, Lu Wang, Maria E. Arcila, et al.. (2015). Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research. 21(16). 3631–3639. 202 indexed citations
14.
Snyder, Alexandra, Vladimir Makarov, Matthew D. Hellmann, et al.. (2015). Genetics and immunology: reinvigorated. OncoImmunology. 4(10). e1029705–e1029705. 7 indexed citations
15.
LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations
16.
Suehara, Yoshiyuki, Maria E. Arcila, Lu Wang, et al.. (2012). Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions. Clinical Cancer Research. 18(24). 6599–6608. 132 indexed citations
17.
Pietanza, M. Catherine, Kyuichi Kadota, Kety Huberman, et al.. (2012). Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Clinical Cancer Research. 18(4). 1138–1145. 122 indexed citations
18.
Paik, Paul K., Charles M. Rudin, M. Catherine Pietanza, et al.. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 74(3). 481–485. 70 indexed citations
19.
Zhao, Binsheng, Geoffrey R. Oxnard, Chaya S. Moskowitz, et al.. (2010). A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development. Clinical Cancer Research. 16(18). 4647–4653. 82 indexed citations
20.
Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology. 27(15). 2523–2529. 194 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott Gettinger Breakdown of academic impact, for papers by José Luis Perez‐Gracia Breakdown of academic impact, for papers by Amita Patnaik Breakdown of academic impact, for papers by Frank G. Haluska Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Kim Margolin Breakdown of academic impact, for papers by Matthew D. Hellmann Breakdown of academic impact, for papers by Craig Devoe Breakdown of academic impact, for papers by Rolf A. Stahel Breakdown of academic impact, for papers by Laura Q.M. Chow
Rankless by CCL
2026